The newly launched Signa PET/MR Air device offers technological features that may bolster image quality and enhance diagnostic accuracy for diseases such as prostate cancer and Alzheimer’s disease.
Offering a variety of reported technological advances to facilitate the diagnosis of conditions such as Alzheimer’s disease and prostate cancer, the Signa PET/MR Air system (GE HealthCare) will be launched at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.
The Signa PET/MR Air system combines the high sensitivity of positron emission tomography (PET) with the anatomical precision offered by magnetic resonance imaging (MRI) in one device, according to GE HealthCare. The company said integrating prostate-specific membrane antigen (PSMA)-targeted PET radiotracer agents with the Signa PET/MR Air system may help optimize staging and facilitate a more precise diagnosis in prostate cancer cases.
Other features of the Signa PET/MR Air system include the Time-of-Flight (TOF) PET detector and MotionFree Brain PET. Addressing patient motion during exams without external tracking devices, MotionFree Brain PET enables consistent image quality, which reduces repeat scans and may potentially improve diagnostic accuracy for challenging patients, according to the company. GE HealthCare added that the sensitivity of the ToF PET detector can detect adverse effects in a single scan and provide insights into disease progression.
“Our latest PET/MR technology will directly impact the most challenging diseases, such as prostate cancer and Alzheimer’s disease. These diseases require precise and comprehensive imaging for accurate diagnosis, treatment planning, and therapy monitoring,” noted Jie Xue, president and CEO of MR at GE HealthCare. “We are excited to see SIGNA PET/MR AIR addressing these challenges and fulfilling our vision of providing access to advanced, personalized care.”
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
Interventional Radiology Study Shows Low Breast Cancer Recurrence 16 Months After Cryoablation
March 29th 2024In a cohort of patients with invasive breast cancer and tumor sizes ranging between 0.3 to 9 cm, image-guided cryoablation was associated with a 10 percent recurrence rate at 16 months, according to research recently presented at the Society of Interventional Radiology (SIR) conference.
Emerging Insights on MRI-Guided Transurethral Ultrasound Ablation for Prostate Cancer
March 21st 2024For men with prostate cancer, the use of MRI-guided transurethral ultrasound ablation (TULSA) led to a 92 percent decrease in median prostate volume at one year, according to new research recently presented at Society of Interventional Radiology (SIR) conference.
Could Cloud-Based 'Progressive Loading' be a Boon for Radiology Workflows?
March 13th 2024The newly launched Progressive Loading feature, available through RamSoft’s OmegaAI software, reportedly offers radiologist rapid uploading of images that is faster than on-site networks and other cloud-based systems regardless of the network radiologists are using.
ECR Study Finds Mixed Results with AI on Breast Ultrasound
March 6th 2024While adjunctive use of AI led to significantly higher specificity and accuracy rates in detecting cancer on breast ultrasound exams in comparison to unassisted reading by breast radiologists, researchers noted that 12 of 13 BI-RADS 3 lesions upgraded by AI were ultimately benign, according to research presented at the European Congress of Radiology.